.jpg)
Tissue Intelligence™,
where and when it matters most.
Ziva is a Tissue Intelligence™ company. Our investigational Elora® Breast System is under development and is intended to help surgeons identify residual cancer inside the cavity following tumour removal, at the moment the decision is being made - what additional tissue to remove, what to preserve. Elora® aims to help guide the surgeon to remove all the cancer the first time.
THE PROBLEM
The Problem We’re Solving
1 in 5
BCS patients need a second operation to remove more cancerous tissue ¹
Surgeons remove tumours largely by feel, making it difficult to discern in the moment, if they have removed all the cancerous tissue, the first time. When cancerous tissue has been left behind, the patient may face a second operation.
2x
Higher risk of local recurrence if cancer left behind ²
THE SOLUTION
Our Solution
.png)
During breast-conserving surgery, the Elora® Breast System is designed to give surgeons real-time, high-resolution imaging of tissue as they operate, helping them to distinguish diseased tissue from healthy tissue in the moment a decision is being made. Elora® is designed to integrate into the surgical workflow and to complement pathology rather than replace it. The goal is more patients moving forward after a single surgery, confident their cancer is behind them.
Our focus today is breast cancer. Our intention is to extend the Elora® Platform to other solid cancer tumour indications.
THE TECHNOLOGY
And the technology behind it
Quantitative Micro-Elastography
The Elora® System is built on QME, combining two established techniques: Optical Coherence Tomography, which uses light to produce a microscale view of tissue architecture, and micro-elastography, which measures the stiffness of that tissue. Cancerous tissue is typically stiffer than the healthy tissue around it ³ ⁴, and Ziva is assessing whether combining the two techniques can help surgeons identify residual cancer after tumour removal before leaving surgery.
MEET THE CEO
"Ziva means light, and that's exactly what we do; bring light to what a surgeon cannot otherwise see, in the moment it matters most."
Dr Katharine Giles
MD/MBA, Managing Director & CEO
Sources
¹ Kim, Y., Ganduglia-Cazaban, C., Tamirisa, N., Lucci, A., & Krause, T. M. (2024). Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery. Annals of surgical oncology, 1-12.
² Bundred JR, Michael S, Stuart B, Cutress RI, Beckmann K, Holleczek B, Dahlstrom JE, Gath J, Dodwell D, Bundred NJ. Margin status and survival outcomes after breast cancer conservation surgery: prospectively registered systematic review and meta-analysis. BMJ. 2022 Sep 21;378:e070346. doi: 10.1136/bmj-2022-070346. PMID: 36130770; PMCID: PMC9490551
³ Sayed, A., Layne, G., Abraham, J., & Mukdadi, O. (2013). Nonlinear characterization of breast cancer using multi-compression 3D ultrasound elastography in vivo. Ultrasonics, 53(5), 979–991. https://doi.org/10.1016/j.ultras.2013.01.005
⁴ Srivastava, A., Verma, Y., Rao, K. D., & Gupta, P. K. (2011). Determination of elastic properties of resected human breast tissue samples using optical coherence tomographic elastography. Strain, 47(1), 75–87. https://doi.org/10.1111/j.1475-1305.2009.00627.x